PSA Screening Controversy Continues

Should you have a PSA test? For most of the past fifteen years the honest answer has been “it depends”, and the two bodies that most shape U.S. practice still frame it differently. This page explains what each recommends today, why they differ, and how we approach the decision with patients.

What a PSA test is

PSA (prostate-specific antigen) is a protein made mostly by the prostate. A blood test measures its level. A raised PSA can be a sign of prostate cancer, but it can also come from an enlarged prostate, inflammation or infection, so it is a signal to look further, not a diagnosis.

What screening can and cannot do

The U.S. Preventive Services Task Force (USPSTF) summarises the trade-off this way: screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men, while many men will experience potential harms, including false-positive results that lead to more testing and possible biopsy, overdiagnosis and overtreatment, and treatment complications such as incontinence and erectile dysfunction.¹

Both sides of that are true at once. Prostate cancer is common and often slow-growing, and many men die with it rather than of it. A PSA test can also catch an aggressive cancer while it is still curable. That is why every current guideline begins with shared decision-making.

What the USPSTF recommends

The Task Force’s current recommendation dates from May 2018:¹

• Men aged 55 to 69 (grade C): the decision to undergo periodic PSA-based screening should be an individual one, made after discussing the potential benefits and harms with a clinician.
• Men 70 and older (grade D): the USPSTF recommends against PSA-based screening.

The Task Force’s website notes that this topic is being updated. As of October 2026 the update had reached the research-plan stage, and no draft recommendation had been published.²

What the AUA and SUO recommend

The American Urological Association and the Society of Urologic Oncology published their early-detection guideline in 2023 and amended it in 2026. Its screening statements say that clinicians:³

• should engage in shared decision-making and proceed based on a person’s values and preferences;
• should use PSA as the first screening test;
• should repeat a newly elevated PSA before a further biomarker, imaging or biopsy;
• may offer a baseline PSA between 45 and 50;
• should offer screening from 40 to 45 for people at increased risk: Black men, men with germline mutations, and men with a strong family history of prostate cancer;
• should offer regular screening every 2 to 4 years from 50 to 69;
• may personalise the interval, or stop screening, based on preference, age, PSA, risk, life expectancy and general health.

Where the two agree and differ

The two agree on the most important point: the decision should be made together, with the man’s own values in view. They differ mainly in emphasis and in age range. The AUA/SUO guideline starts the conversation earlier and frames regular screening as something to offer; the Task Force frames it as an individual choice in a narrower age band.

If your PSA comes back high

A single high reading is a starting point. The AUA/SUO guideline advises repeating it first.³ After that, several tools can help decide whether a biopsy is needed, and where to aim it:

• MRI before biopsy, which the guideline says clinicians may use before a first biopsy to improve detection of clinically significant cancer.³
• Blood or urine biomarkers such as the 4Kscore, when the result would change the decision.³
• A targeted biopsy of any suspicious area seen on MRI, using MRI-ultrasound fusion.³

Research continues on new imaging; a 2026 trial of PSMA-PET before biopsy is one example.

A short history of the PSA debate, 2008–2018

This blog covered the screening debate as it happened, and several of those posts now redirect here. In brief:

• 2008. The USPSTF found the evidence insufficient to judge screening in men under 75, and recommended against it at 75 and older.⁴
• 2011. A draft released on October 7, 2011, proposed a grade D, against PSA screening for all men. The AUA strongly opposed it, and the draft drew thousands of public comments.⁶⁷
• 2012. The final recommendation was against PSA-based screening for men of any age (grade D).⁵
• 2018. The Task Force revised its position to the current one: an individual decision at 55 to 69, against at 70 and older.¹

The 2018 shift toward shared decision-making, together with MRI, biomarkers and active surveillance for low-risk cancers, has changed what screening means in practice. Many of the harms that fuelled the 2011 debate came from treating every cancer found. Today the guideline asks urologists to tell men before a biopsy that it may find a low-risk cancer that can be safely monitored with active surveillance rather than treated.³

Questions to bring to your appointment

• Given my age, race and family history, what is my risk?
• Do I carry any known genetic mutation that changes the advice?
• What would we do if the result came back high?
• If a cancer were found, would it need treatment, or could it be monitored?
• How often should I be retested, and when could I stop?